Presentation Information
[C2-01]Longitudinal monitoring of cellular immunity by the ex vivo activation of genes in leukocytes (EAGL) assay highlights potential markers of mRNA COVID-19 vaccine efficacy against breakthrough symptoms
*Taro Saito1, Arnaud Couzinet2, Toshihiro Suzuki2, Kei Miyakawa3, Tetsuya Nakatsura2 (1. Canon Medical Diagnostics Corporation (Japan), 2. Division of Cancer Immunotherapy, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center (Japan), 3. Influenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security (Japan))
Keywords:
Cellular immunity,mRNA vaccine,SARS-CoV-2,EAGL assay
Password required to view
Log in
or
Comment
To browse or post comments, you must log in.Log in